Nautilus Biotechnology Reports Third Quarter 2025 Financial Results (Form 8-K)

Nautilus Biotechnology Reports Third Quarter 2025 Financial Results

SEATTLE, WA, October 28, 2025 - Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2025.

Third Quarter 2025 Business Highlights

•Continued progress was made in processing Tau proteoform samples from collaborators in support of our goals of product validation and growing our publications. We expect to share this data at the upcoming World HUPO conference.

•Further progress was made in the development of a new broadscale assay format, which is intended to support our forthcoming commercial launch in late 2026.

•We expect to launch our early access program with Tau proteoforms in the first half of 2026.

"In Q3, Nautilus maintained disciplined execution and delivered meaningful progress across our platform, strategic collaborations, and operational initiatives-all aligned with our path toward commercialization in late 2026," said Sujal Patel, CEO of Nautilus Biotechnology. "Our near-term focus is on the successful launch of our early access program, beginning with Tau proteoforms in the first half of 2026 and expanding to broadscale capabilities later in the year. These milestones are critical steps toward enabling customers to experience the value of our technology and advancing toward full commercial availability."

Third Quarter 2025 Financial Results

Operating expenses were $15.5 million for the third quarter of 2025, a 19% decrease compared to $19.1 million for the corresponding prior year period. The decrease in operating expenses is attributable to operating efficiencies, lower development-related costs, and decreased salaries, related benefits and stock-based compensation.

Net loss was $13.6 million for the third quarter of 2025, as compared to the net loss of $16.4 million for the corresponding prior year period.

Cash, cash equivalents, and investments were $168.5 million as of September 30, 2025.

Webcast and Conference Call Information

Nautilus will host a conference call to discuss the third quarter 2025 financial results, business developments and outlook before market open on Tuesday, October 28, 2025, at 5:30 AM Pacific Time / 8:30 AM Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio.

About Nautilus Biotechnology, Inc.

With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus' mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio

Special Note Regarding Forward-Looking Statements